Dr. Seth M. Pollack
Claim this profileNorthwestern University
Area of expertise
Soft Tissue Sarcoma
Seth M. Pollack has run 7 trials for Soft Tissue Sarcoma. Some of their research focus areas include:
Cancer
Seth M. Pollack has run 6 trials for Cancer. Some of their research focus areas include:
Affiliated Hospitals
Northwestern University
Northwestern Medicine Cancer Center Kishwaukee
Clinical Trials Seth M. Pollack is currently running
ADI-PEG 20 + Chemotherapy
for Leiomyosarcoma
To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
Recruiting
1 award
Phase 3
10 criteria
Immunotherapy + Chemotherapy
for Sarcoma
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding immunotherapy (pembrolizumab) to the standard chemotherapy (doxorubicin) may help patients with metastatic or unresectable DDLPS, UPS or a related poorly differentiated sarcoma live longer without having disease progression.
Recruiting
2 awards
Phase 3
10 criteria
More about Seth M. Pollack
Clinical Trial Related
2 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Seth M. Pollack has experience with
- Cabozantinib
- Placebo
- Doxorubicin
- Temozolomide
- Nivolumab
- Dacarbazine
Breakdown of trials Seth M. Pollack has run
Soft Tissue Sarcoma
Cancer
Uterine Leiomyosarcoma
Leiomyosarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Seth M. Pollack specialize in?
Seth M. Pollack focuses on Soft Tissue Sarcoma and Cancer. In particular, much of their work with Soft Tissue Sarcoma has involved Stage IV patients, or patients who are Stage III.
Is Seth M. Pollack currently recruiting for clinical trials?
Yes, Seth M. Pollack is currently recruiting for 4 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Seth M. Pollack has studied deeply?
Yes, Seth M. Pollack has studied treatments such as Cabozantinib, Placebo, Doxorubicin.
What is the best way to schedule an appointment with Seth M. Pollack?
Apply for one of the trials that Seth M. Pollack is conducting.
What is the office address of Seth M. Pollack?
The office of Seth M. Pollack is located at: Northwestern University, Chicago, Illinois 60611 United States. This is the address for their practice at the Northwestern University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.